Fulcrum Therapeutics (NASDAQ:FULC) Upgraded at Leerink Partners

Leerink Partners upgraded shares of Fulcrum Therapeutics (NASDAQ:FULC) from a market perform rating to an outperform rating in a report published on Friday morning, MarketBeat.com reports. They currently have $12.00 price objective on the stock, up from their prior price objective of $4.00.

A number of other brokerages have also weighed in on FULC. HC Wainwright reiterated a “neutral” rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a research report on Wednesday, February 26th. Cantor Fitzgerald upgraded Fulcrum Therapeutics from a “neutral” rating to an “overweight” rating and set a $10.00 price objective on the stock in a research report on Thursday, May 15th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Fulcrum Therapeutics currently has an average rating of “Hold” and an average target price of $5.83.

Fulcrum Therapeutics Price Performance

Shares of Fulcrum Therapeutics stock opened at $6.44 on Friday. The business’s 50 day simple moving average is $4.03 and its two-hundred day simple moving average is $3.91. The stock has a market capitalization of $347.62 million, a P/E ratio of -20.77 and a beta of 2.29. Fulcrum Therapeutics has a one year low of $2.32 and a one year high of $10.13.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.01. Sell-side analysts expect that Fulcrum Therapeutics will post -0.16 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Fulcrum Therapeutics

Hedge funds have recently made changes to their positions in the company. MetLife Investment Management LLC boosted its position in shares of Fulcrum Therapeutics by 145.8% during the fourth quarter. MetLife Investment Management LLC now owns 40,107 shares of the company’s stock valued at $189,000 after purchasing an additional 23,792 shares in the last quarter. American Century Companies Inc. boosted its position in shares of Fulcrum Therapeutics by 5.9% during the fourth quarter. American Century Companies Inc. now owns 120,611 shares of the company’s stock valued at $567,000 after purchasing an additional 6,770 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Fulcrum Therapeutics by 34.4% during the fourth quarter. Wells Fargo & Company MN now owns 34,264 shares of the company’s stock valued at $161,000 after purchasing an additional 8,761 shares in the last quarter. Northern Trust Corp boosted its position in shares of Fulcrum Therapeutics by 25.1% during the fourth quarter. Northern Trust Corp now owns 710,321 shares of the company’s stock valued at $3,339,000 after purchasing an additional 142,578 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of Fulcrum Therapeutics by 46.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 52,368 shares of the company’s stock valued at $247,000 after purchasing an additional 16,656 shares in the last quarter. 89.83% of the stock is currently owned by institutional investors.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.